Navigation Links
Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
Date:10/5/2007

RIDGEFIELD, Conn., Oct. 5 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted full (traditional) approval of Aptivus(R) (tipranavir) capsules. The FDA granted accelerated approval to APTIVUS in June 2005; accelerated approval is a regulatory process that expedites the approval of therapies for serious or life-threatening illnesses. The full approval of APTIVUS is based largely on 48-week analyses of the Phase 3 pivotal clinical studies known as the RESIST (Randomized Evaluation of Strategic Intervention in Multi-Drug ReSistant Patients with Tipranavir) trials. These trials comprise one of the largest study programs conducted in treatment-experienced HIV patients.

"Data show that APTIVUS/r may provide treatment-experienced HIV patients with an effective treatment option through nearly one year of therapy. Furthermore, longer-term safety data are now available for physician and patient consideration," said Dr. Daniel Kuritzkes, associate professor of medicine, Harvard Medical School; director of AIDS research, Brigham and Women's Hospital, Boston, MA.

APTIVUS, a protease inhibitor, co-administered with 200 mg of ritonavir (APTIVUS/r), is indicated for combination antiretroviral treatment of HIV-1 infected adult patients who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor.

This indication is based on analyses of plasma HIV-1 RNA levels in two controlled studies of APTIVUS/r of 48 weeks duration. Both studies were conducted in clinically advanced, 3-class antiretroviral (NRTI, NNRTI, PI) treatment-experienced adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

The following points should be considered when initiating therapy with APTIVUS/r:

-- The use of APTIVUS/r in treatment-nave patients is not recommended.

-- The use of other active agents with APTIVUS/r is as
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
2. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
3. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced it ... adults suffering from the severe cold weather that has gripped ... to helping those in need; so to support these emergency ... up to $250,000, which could mean up to $500,000 in ...
(Date:1/15/2014)... 2014  Celsion Corporation (the "Company") (NASDAQ: CLSN ... institutional investors to purchase an aggregate of approximately $15 ... registered direct offering, led by a dedicated health care ... agreements with these investors pursuant to which the Company ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Reportlinker.com announces that a new market research report is available ... http://www.reportlinker.com/p0324750/Virtual-Pharma.html ... in the pharmaceutical market has slowed – almost to a ... cutting costs in a faltering world economy. ...
... NEW YORK, Nov. 3, 2010 Pfizer Inc. (NYSE: ... public to view and listen to a webcast of ... Primary Care, at the 2010 Annual Credit Suisse Healthcare ... Mountain Standard Time. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) ...
Cached Medicine Technology:Reportlinker Adds Virtual Pharma 2Reportlinker Adds Virtual Pharma 3Reportlinker Adds Virtual Pharma 4Reportlinker Adds Virtual Pharma 5Reportlinker Adds Virtual Pharma 6
(Date:4/17/2014)... targets that could be used to provide relief ... London made the discovery when researching how pain ... body. , Dr Marzia Malcangio said: "We have ... and our findings could help chemotherapy patients who ... side effect of some chemotherapy drugs (such as ...
(Date:4/17/2014)... the April issue of Experimental Biology and ... Drs. Rex Gaskins and Paul Kenis in the ... of the University of Illinois Urbana-Champaign describe their ... reactions underlie a variety of cell functions including ... these crucial roles in regulating normal cellular behavior, ...
(Date:4/17/2014)... NY In a review published in the April ... president of The Feinstein Institute for Medical Research, says ... medical community,s approach to treating sepsis, which ... Americans. , Sepsis occurs when molecules released into the ... throughout the body. Inflammation is necessary for maintaining good ...
(Date:4/17/2014)... 2014U.S. military personnel who served in Iraq and ... brain injury (TBI) were compared to military personnel ... reasons. Differences in measures of overall disability, cognitive ... injury are reported in an article in ... Mary Ann Liebert, Inc., publishers. The article is ...
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2
... Air pollution could be putting patients with heart disease at ... , A study by the University of Edinburgh and Ume ... blood vessel function in men who have previously experienced a ... Heart Foundation and published in the New England Journal of ...
... Armed with satellite imagery, field samples, human Lyme disease ... from the University of New Hampshire, the New Hampshire ... sector will conduct work on the ecology and risk ... states in an effort to eventually identify "hot spots" ...
... Quilt a ,Beautiful Symbol, NEW YORK, Sept. 12 ... Bolds, as "a homemaker." Doing,everything the old-fashioned way, Aylene ... a clothes line, washing and drying her dishes,by hand, ... aroma from the kitchen met you at the front ...
... Where do personal,trainers go to gain more knowledge? Well, ... sciences relating to fitness from conferences, trade,associations and certifying ... list. PersonalTrainerTV.com is a new membership web site for,fitness ... from leading,experts in the industry. According to its ...
... 2007 Approximately 30% of Canadians suffer daily from ... the intensity, but all chronic pain is debilitating and ... Lamb, a clinician nurse at the Pain Centre of ... Shir, the Director of the Centre, shows that methadone ...
... PORTLAND, Maine, Sept. 12 JHA has released the ... Survey. This leading,benchmarking survey reports group Long Term Disability ... premium results for the first,half of the year. The ... of the top twenty carriers, as ranked by inforce ...
Cached Medicine News:Health News:Diesel exhaust may increase risk in patients with heart disease 2Health News:UNH, state health agency, private industry and NASA to tackle Lyme disease 2Health News:UNH, state health agency, private industry and NASA to tackle Lyme disease 3Health News:UNH, state health agency, private industry and NASA to tackle Lyme disease 4Health News:Alzheimer's Foundation of America to Display Quilt to Remember in Los Angeles 2Health News:Alzheimer's Foundation of America to Display Quilt to Remember in Los Angeles 3Health News:Methadone and systematic follow-up: the best solution for managing chronic pain 2Health News:JHA Releases 2007 U.S. Group Disability Mid-Year Market Survey Results 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: